Enables a potentially scalable model for the widespread adoption of psychedelic treatments
The Company will host Investor Update on Tuesday, October 4thth
KELOWNA, British Columbia, Oct. 3, 2022 (GLOBE NEWSWIRE) — tryp therapeuticsinc TRYP TRYPF (“Attempt” or the “company“), a clinical-stage biotechnology company focused on the development of psilocybin-based compounds for diseases with unmet medical needs, announced today that the World Intellectual Property Organization (WIPO) has filed its international patent application (PCT/IB2022/052347) which covers intravenous administration of psilocybin and psilocin The PCT application, entitled “Improved Methods For The Use of Psychedelics,” expands and strengthens intellectual property related to the Company’s development of TRP-8803, an IV -Formulation of psilocin administered in conjunction with psychotherapy.
The patent application covers a unique and proprietary formulation and delivery system to amplify the beneficial effects of psilocybin, and psilocin in particular, while significantly reducing the limitations of psilocybin dosed via other routes of administration, including oral, nasal and sublingual. Oral administration, while convenient, has several limitations and challenges that TRP-8803 can address, including:
Controlling the time to onset of psychedelic experiences
- Oral administration of psilocybin can take 1 to 2 hours to induce the psychedelic state; Intravenous infusion can shorten this period to 30 minutes.
Managing the duration of the psychedelic experience
- When given orally, the psychedelic state, once initiated, can last 6-8 hours, a significant burden for the patient and the two psychotherapists; IV administration allows the practitioner to control the duration of the psychedelic state, potentially shortening the total duration to 1-2 hours.
Achieve clinically validated blood levels of psilocin
- When administered orally, psilocybin bioavailability may be reduced due to first-pass metabolism in the liver. Psilocybin is a…
